Programmed Cell Death Protein 1 Inhibitor

DRUG2 trials

Sponsors

The Central Hospital of Lishui City, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Carcinoma, Non-Small-Cell LungConcurrent ChemoradiotherapyImmunonutritionLocally Advanced Esophageal Squamous Cell CarcinomaRadiotherapySintilimab

Phase 2

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

Active, not recruitingNCT06342167

Cancer Institute and Hospital, Chinese Academy of Medical SciencesConcurrent Chemoradiotherapy, Immunonutrition, Locally Advanced Esophageal Squamous Cell Carcinoma +2

Start: 2024-03-14End: 2026-12-01Target: 57Updated: 2024-06-11

Unknown Phase

Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure

Not yet recruitingNCT05248022

The Central Hospital of Lishui CityCarcinoma, Non-Small-Cell Lung

Start: 2024-02-01End: 2024-12-31Target: 98Updated: 2024-01-09

Related Papers

Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial

Radiation Oncology2025-04-182 citations